🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
92.49
+0.54 (0.59%)
At close: Nov 18, 2026, 4:00 PM EST
92.60
+0.11 (0.12%)
After-hours: Nov 18, 2026, 4:32 PM EST

Company Description

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.

Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis.

In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS.

The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.

Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals logo
CountryUnited States
Founded2018
IPO DateJul 18, 2019
IndustryBiotechnology
SectorHealthcare
Employees470
CEOChristopher Peetz

Contact Details

Address:
989 East Hillsdale Boulevard, Suite 300
Foster City, California 94404
United States
Phone650 667 4085
Websitemirumpharma.com

Stock Details

Ticker SymbolMIRM
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$15.00
CIK Code1759425
CUSIP Number604749101
ISIN NumberUS6047491013
Employer ID83-1281555
SIC Code2834

Key Executives

NamePosition
Christopher PeetzChief Executive Officer and Director
Peter Radovich M.B.A., Ph.D.Chief Operating Officer and President
Eric H. Bjerkholt M.B.A., M.S.Chief Financial Officer
Dr. Jean-Luc Girardet Ph.D.Chief Technical Officer
Andrew McKibbenSenior Vice President, Strategic Finance and Investor Relations
Douglas T. Sheehy J.D.Chief Legal Officer and Secretary
Meredith KiernanSenior Director of Global Corporate Communications
Erin CampanyChief People Officer
Lara Longpre MBA, MSCChief Development Officer
Vinita P. KumarSenior Vice President of Quality

Latest SEC Filings

DateTypeTitle
Nov 16, 2026144Filing
Nov 16, 2026SCHEDULE 13G/AFiling
Nov 12, 2026144Filing
Nov 10, 20268-KCurrent Report
Nov 4, 2026144Filing
Nov 4, 2026144Filing
Nov 3, 202610-QQuarterly Report
Nov 3, 20268-KCurrent Report
Oct 26, 20268-KCurrent Report
Oct 13, 20268-KCurrent Report
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides